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In the peripheral nervous system (PNS), Schwann cells (SCs) 
encase large-caliber axons with myelin. This essential multil-
amellar membrane structure allows for fast saltatory conduc-
tion of action potentials and contributes to intricate reciprocal 
SC-axon interactions, both central to PNS function (Pereira 
et al., 2012; Nave and Werner, 2014; Monk et al., 2015; Her-
bert and Monk, 2017). Myelination is an expensive metabolic 
process, demanding increased and precisely coordinated RNA 
and protein synthesis, epigenetic modifications, protein tar-
geting, and massive membrane production (Taveggia et al., 
2010; Nave and Werner, 2014). Notably, myelin membranes 
are enriched in lipids compared with other cells (Chrast et al., 
2011; Nave and Werner, 2014; Schmitt et al., 2015) and pos-
sess a rather unique relative lipid composition (Chrast et al., 
2011; Nave and Werner, 2014; Schmitt et al., 2015). These 
observations indicate that lipid synthesis and/or uptake in my-
elinating glial cells is likely to be tightly regulated. Nonethe-
less, the contribution of lipid synthesis, as opposed to uptake, 
and the molecular mechanisms underlying the distinctive lipid 
composition of myelin membranes are not clear. The mam-
malian target of rapamycin (mTOR) is a critical regulator of 
a plethora of lipogenic enzymes. In particular, mTOR com-
plex 1 (mTORC1) appears to be important for modulating 
cholesterol and fatty acid (FA) synthetic pathways, including 
in myelinating cells (Laplante and Sabatini, 2012; Norrmén 
and Suter, 2013; Lebrun-Julien et al., 2014; Shimobayashi 
and Hall, 2014; Schmitt et al., 2015). In line with a potential 
critical role for overall lipogenesis, we and others have shown 
that mTOR (Sherman et al., 2012), mTORC1 (Norrmén et 
al., 2014; Figlia et al., 2017), SCAP (Verheijen et al., 2009), 
and the SCAP target SRE BP1c (Cermenati et al., 2015) are 
each required for timely PNS myelin development. The func-
tional roles of individual lipogenic enzymes and specific lipid 
species in this process are poorly understood (Schmitt et al., 
2015). SCs lacking squalene synthase, necessary for choles-
terol synthesis, exhibit reduced myelin growth (Saher et al., 
2009; Schmitt et al., 2015). This phenotype recovers in adult-
hood, similar to findings in SCAP mutant mice (Verheijen et 
al., 2009; Schmitt et al., 2015). Glycolipids and phospholip-
ids together comprise the largest proportion of myelin mem-
brane lipids and both require FAs for their synthesis. Although 
various facets have been analyzed in the past, the functional 
role of endogenous FA synthesis in myelinating glia has not 
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been addressed. Cells mostly derive FAs from dietary sources 
(Currie et al., 2013). However, most FAs, referred to as non-
essential FAs, can also be synthesized intracellularly. Fatty 
acid synthase (FASN) is responsible for the catalysis of all 
seven steps leading to the synthesis of 16-carbon palmitic 
acid, beginning with the condensation of acetyl–coenzyme A 
and malonyl–coenzyme A.  Palmitic acid is the substrate for 
the synthesis of more complex nonessential FAs (Currie et al., 
2013). Under increased lipid demand, e.g., a high prolifera-
tive rate, cells are capable of up-regulating FASN. Thus, both 
progenitor (Knobloch et al., 2013) and cancer (Menendez and 
Lupu, 2007; Currie et al., 2013) cells rely on FASN activity for 
proliferation, and FASN inhibitors are currently under study 
as potential anticancer therapies (Menendez and Lupu, 2007; 
Currie et al., 2013). Notably, FAs can be used for purposes 
beyond membrane lipid production. They can also affect gene 
transcription in a tissue-specific manner via modulation of the 
activity of nuclear peroxisome proliferator-activated receptors 
(PPARα, β, and γ; Ahmadian et al., 2013).
Because of their high rates of membrane production, the 
high lipid content of their membranes, and their peculiar rela-
tive lipid composition, we hypothesized that SCs rely critically 
on endogenous FA synthesis during development, rather than 
solely on FA uptake. Indeed, both FASN and PPARγ are ex-
pressed in myelinating SCs (Verheijen et al., 2003; Yamagishi 
et al., 2008; Cao et al., 2012; Nave and Werner, 2014), and the 
level of FASN expression in the PNS is temporally linked to 
the myelination process (Salles et al., 2002). These observa-
tions prompted us to investigate the specific role of FASN-me-
diated de novo FA synthesis in SC myelination. To this end, 
we examined the functional consequences of conditional deple-
tion of FASN in SCs in vivo, in conjunction with molecular 
mechanisms associated with this alteration. Our data identified 
FASN-mediated FA synthesis in SCs as a fundamental prerequi-
site for correct myelination. Moreover, we found that lipogenic 
activation of the PPARγ transcriptional network is a putative 
contributor to this process.
Results
De novo FA synthesis in SCs is required 
for fully functional PNS development
We first addressed the role of de novo FA synthesis in PNS 
myelination by conditionally ablating Fasn in SCs in vivo 
(called mutant hereafter). Mice carrying floxed Fasn alleles 
(Chakravarthy et al., 2005) were crossed with mice expressing 
Cre recombinase under the control of Desert hedgehog (Dhh) 
gene regulatory sequences (Jaegle et al., 2003; Fig. 1 a). Loss 
of FASN expression in SCs of sciatic nerves of mutant mice 
was confirmed by immunoblotting (Fig. 1 b) and immunohis-
tochemistry (Fig.  1  d). Mutant mice were viable and fertile, 
with litters born according to expected Mendelian distributions. 
However, qualitative phenotypic analysis revealed abnormal 
hindlimb clasping upon tail-lift (Fig. 1 c). In parallel, we found 
that mutants displayed moderately decreased forelimb muscu-
lar peak force in a grip-strength test (Fig. 1 e) and decreased 
latency to fall from an accelerating Rotarod compared with 
controls (Fig. 1 f). Together, these results are consistent with a 
requirement of accurate FASN activity in SCs to achieve com-
plete PNS function during development.
FA synthesis is largely dispensable for SC 
survival and proliferation
During early postnatal development, SCs undergo extensive 
proliferation. Reaching a threshold number is thought to be a 
limiting factor for successful SC-axon sorting, i.e., the process 
by which SCs segregate out large-caliber axons from axonal 
bundles into a one-to-one (SC-to-axon) promyelinating rela-
tionship, the developmental step preceding onset of myelination 
(Benninger et al., 2007; Feltri et al., 2016). Because synthesis of 
FAs is critical for other highly proliferative cells, we analyzed 
SC proliferation and survival at birth and postnatal day 5 (P5). 
However, we found no detectable differences between mutants 
and controls (Fig. S1, a and b). As such, we conclude that FASN 
and de novo FA synthesis are not required for SC proliferation 
and survival in early postnatal PNS development.
De novo FA synthesis in SCs is essential 
for the correct onset of PNS myelination
To characterize whether FASN is required at later stages of SC de-
velopment and/or for myelination, we analyzed the ultrastructural 
morphology of mutant and control sciatic nerves by comparative 
EM. Consistent with the unaltered SC proliferation and survival, 
mutants showed no overt defects in axonal segregation. Instead, 
we found a major impairment in myelination onset and mild ef-
fects on myelin growth (Fig. 2). In P5 control nerves, 57.59 ± 
5.84% of sorted SC-axon units had started myelination, whereas 
only 34.80 ± 2.88% had progressed to this stage in mutants 
(Fig. 2, a and b). In addition, mutant myelinating SCs showed 
overall thinner myelin compared with controls. Quantification 
by g-ratio analysis (a conventional measure of myelin thickness, 
i.e., axon diameter/[axon + myelin] diameter) confirmed sub-
stantial hypomyelination (Fig.  2, c and d). As development of 
sciatic nerves progressed, practically all large-caliber axons be-
came myelinated in controls at P14. In contrast, ∼25% of sorted 
SC-axon units remained arrested at the promyelinating stage in 
P14 mutant nerves (27.02 ± 1.94% in mutants vs. 1.69 ± 0.51% 
in controls; Fig. 2 a [arrows] and b). Hypomyelination was still 
present (Fig. 2, a [arrowheads] and c), but a significant increase in 
the mean g-ratio was found only if axons >3 µm in diameter were 
analyzed as a group (Fig. 2 d). These features remained stable in 
adolescent (P24) and adult (P180; Fig. 2, a–d) control and mutant 
nerves, confirming a major block at the onset of myelination in 
a subset of myelination-competent SCs, together with consistent, 
albeit mild, hypomyelination. To corroborate the morphological 
data, we examined the expression of the octamer-binding tran-
scription factor Oct6 that is normally present at high levels in pro-
myelinating SCs, but down-regulated once the cells shift toward 
a myelinating phenotype (Jessen and Mirsky, 2005). Indeed, we 
found increased amounts of Oct6 in protein lysates from sciatic 
nerves of P40 mutants compared with controls by immunoblot-
ting (Fig. S1 c). We conclude that SC-intrinsic FASN plays mul-
tiple important roles in nerve development, including a striking 
effect on the onset of myelination.
De novo FA synthesis in SCs is not majorly 
important for axonal maintenance
Next, we examined whether FA synthesis in SCs contributes to 
myelin-supported axonal maintenance. Although we observed, 
at a very low frequency, some stressed axons presumably com-
pressed because of myelin vacuolization and/or splitting in mu-
tants (Fig. S1, d and e), the total number of sorted axons (i.e., at 
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the myelinating or promyelinating stage) per P180 sciatic nerve 
cross section did not differ between controls and mutants (Fig. 
S1, f). Our findings indicate that FASN activity in SCs is not 
crucial for the maintenance of sorted axons, at least until P180.
SCs in nerve roots are more strongly 
reliant upon de novo FA synthesis than 
SCs in distal nerves
SCs in distal nerves are directly derived from neural crest pre-
cursors, whereas SCs located in the nerve roots are derived in 
large part from boundary cap cells (Maro et al., 2004; Aquino et 
al., 2006; Jacob, 2015). Thus, we asked whether SCs located in 
the roots would show a similar dependence upon FA synthesis as 
observed in distal nerves. First, we analyzed the ultrastructure of 
dorsal (sensory) lumbar roots (DRs) and ventral (motor) lumbar 
roots (VRs) at P24 and P180 by EM. Roots from control mice 
displayed extensive myelination at P24 and P180 (Fig. 3 a). In 
mutants, however, both DRs and VRs contained many sorted 
SC-axon units aberrantly arrested at the promyelinating stage. 
Quantification revealed 60–70% of sorted SC-axon units af-
fected in this way (in P24 DRs: 61.38 ± 5.53% in mutants vs. 
0.0 ± 0.0% in controls; in P24 VRs: 60.86 ± 1.85% in mutants 
vs. 0.0 ± 0.0% in controls; in P180 DRs: 67.34 ± 6.48% in mu-
tants vs. 0.0 ± 0.0% in controls; and in P180 VRs: 65.49 ± 9.79% 
in mutants vs. 0.0 ± 0.0% in controls; Fig. 3, a [arrows] and b). 
Consistent with these morphological findings, immunoblotting 
revealed increased expression of Oct6 and reduced expression 
of the PNS myelin protein PMP22 in protein lysates of roots of 
P40 mutants compared with control mice (Fig. 3 e). Moreover, 
the myelinated fibers present in the mutant roots were hypomy-
elinated (Fig. 3, c and d), but we did not observe obvious signs 
of potential de- and remyelination. Interestingly, these myelin-
ated fibers were stereotypically positioned, framing an increased 
number of nerve blood vessels (Fig. 3, f–h), consistent with a 
possible compensatory role for uptake of FA from blood.
The more pronounced phenotype in the nerve roots 
compared with distal nerves might be ascribed to different 
metabolic demands of SCs and/or to the presence of diverse 
compensating mechanisms. The latter prompted us to exam-
ine the nerve epineurium in which adipocytes accumulate after 
birth (Nadra et al., 2012). We found that these cells displayed a 
mature morphology in sciatic nerves of control mice (P24), with 
a single large lipid globule (Cristancho and Lazar, 2011; Rosen 
and Spiegelman, 2014; Fig. 4, a and b). In contrast, P24 mutant 
nerves contained numerous epineurial adipocytes with multiple 
lipid droplets surrounded by cytoplasm (Fig. 4, a and b), a char-
acteristic of adipocytes undergoing lipolysis (Cristancho and 
Lazar, 2011; Rosen and Spiegelman, 2014). Oil-Red-O stain-
ing of epineuria of P24 and P180 sciatic nerves of controls and 
mutants was consistent with the presence of large numbers of 
adipocytes (Fig. 4 c, arrows). Interestingly, however, both VRs 
and DRs, in controls and mutants, lacked such strong staining, 
suggesting a lack of adipocytes (Fig. 4 c). Given that epineur-
ial adipocytes have no major critical role in myelin formation 
under normal conditions (Nadra et al., 2012), one interpretation 
of these results is that epineurial adipocytes may be able to sup-
port myelination in distal nerves in the absence of de novo FA 
synthesis as a source of supplementary lipids.
Figure 1. De novo FA synthesis in SCs is required for correct PNS function. (a) Conditional Fasn allele inactivation in vivo upon Dhh-driven Cre expression. 
(b) FASN immunoblot and quantification graph, normalized to β-actin, of protein lysates of sciatic nerves (P40). n = 3 blots, each data point represents 
an independent experiment with an independent set of lysates from three control (CT) and three conditional mutant (cMU) mice (unpaired two-tailed two 
sample Student’s t test, P = 0.0044, t = 5.816); **, P < 0.01. (c) Aberrant hindlimb clasping in cMU mice by tail lift. (d) Representative immunostaining of 
cross sectioned sciatic nerves from P14 CT and cMU mice; n = 3 mice for each, CT and cMU. Note the prominent cytoplasmic FASN expression in SCs of 
nerves of CT but not cMU mice. Myelin marker: myelin basic protein, MBP; axonal marker: neurofilament M, NF-M; nuclear marker: DAPI. Bars, 10 µm. (e 
and f) P40 cMU mice showed reduced grip strength (unpaired two-tailed two sample Student’s t test, P = 0.0044, t = 3.310); **, P < 0.01, and decreased 
latency to fall from a Rotarod (two-way ANO VA, trials P = 0.0333, F3,24 = 3.424, Genotype P = 0.01, F1,8 = 11.25, with Bonferroni’s multiple comparisons 
test, trial 1 P < 0.0001, t = 5.284; trial 2 P = 0.0033, t = 3.819; trial 3 P = 0.0001, t = 5.140; trial 4 P = 0.0003, t = 4.747); **, P < 0.01; ***, P < 
0.001, compared with CT. Data points represent n = 9 mice for each, CT and cMU. Bars represent mean ± SEM. 
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Our results show that SCs in nerve roots are more depen-
dent on de novo FA synthesis than SCs in distal nerves. Because 
DRs and VRs were affected similarly, the findings also suggest 
that myelination of distal sensory and motor fibers are compara-
bly reliant on FASN activity. In agreement, saphenous (mainly 
sensory) and quadricep (motor-enriched) nerves shared a com-
parable phenotype among each other (Fig. S2).
De novo FA synthesis in SCs is required 
for accurate lipid composition of 
peripheral nerves
After establishing that FASN activity in SCs is crucial for proper 
myelination in vivo, we explored how SC-intrinsic de novo FA 
synthesis contributes to the lipid composition of nerves. We per-
formed a lipidomic analysis to compare FAs and FA-derived 
lipid classes of sciatic nerves dissected from P24 FASN mutant 
and control mice, after carefully peeling off the epineurium to 
avoid adipocyte contamination (Fig. 5). These studies revealed 
a strong reduction in the content of palmitate, the direct product 
of FASN enzymatic activity, in mutants compared with controls 
(area ratio per milligram of proteins: 21.49 ± 3.67 in mutants 
vs. 37.95 ± 4.61 in controls; Fig. 5 b). Furthermore, the total 
amount of nonessential FAs was robustly decreased in mutant 
nerves (area ratio per milligram of proteins: 78.30 ± 12.64 in 
mutants vs. 138.8 ± 10.68 in controls; Fig. 5 b and Fig. S3), 
because of reductions in long-chain and very-long-chain nones-
sential FAs (Fig. 5 b and Fig. S3). No significant changes were 
detectable in the total amount of essential FAs, derived from 
diet, and conditional-essential FAs (Fig. 5 b and Fig. S3). We 
also found that loss of SC-intrinsic FASN activity affected the 
levels of more complex FA-derived lipid species (Fig. 5, c and d; 
and Fig. S3). Sciatic nerves of mutants displayed a substantially 
reduced content of ceramides (Fig.  5  c and Fig. S3), and the 
ceramide derivatives sphingomyelin and cerebrosides (Fig. 5 c 
and Fig. S3). Mutant mice with defective cerebroside synthesis 
have been shown to display altered PNS nodes of Ranvier, in-
cluding pronounced potassium channel mislocalization shifting 
from juxtaparanodal to paranodal domains, accompanied by 
nerve conduction abnormalities (Bosio et al., 1996; Dupree et 
al., 1998, 1999). However, we did not detect mislocalization 
Figure 2. De novo FA synthesis in nerve SCs is essential to achieve proper PNS myelination. (a) Representative EM images of mutant (cMU) and control 
(CT) sciatic nerve cross sections. Whereas in CT nerves individual large-caliber axons are sorted by SCs to the promyelinating stage (examples indicated 
by arrows) and progressively myelinated, many SCs remain blocked at promyelination in cMU (examples indicated by arrows). cMU nerves also display 
more thinly myelinated axons (examples indicated by arrowheads). Bars, 5 µm. (b) Corresponding graphs with quantification of percentage of SC-axon 
units at the one-to-one versus myelinating stage. Data points represent n = 3 mice for each, CT and cMU, with at least 250 sorted axons quantified in one 
nerve per animal (unpaired two-tailed two sample Student’s t test, P5 cMU vs. CT, P = 0.0249, t = 3.50; P14 cMU vs. CT, P = 0.0002, t = 12.65; P24 cMU 
vs. CT, P = 0.0004, t = 11.29; and P180 cMU vs. CT, P = 0.0006, t = 9.859); *, P < 0.05; ***, P < 0.001. (c) Linear correlation of g-ratio versus axon 
diameter in sciatic nerves of cMU compared with CT. At least 80 myelinated axons per mouse analyzed, three mice for each, CT and cMU. (d) Overall 
hypomyelination at P5 and of grouped larger (≥3 µm in diameter) axons at later stages (P14, P24, and P180) in cMU, as shown by g-ratio analysis. Data 
points represent n = 3 mice for each, CT and cMU (unpaired two-tailed two sample Student’s t test, P5 P = 0.0058, t = 5.376; P14 P = 0.0007, t = 9.449; 
P24 P = 0.0006, t = 9.798; and P180 P = 0.0114, t = 4.438); *, P < 0.05; **, P < 0.01; ***, P < 0.001. Bars represent mean ± SEM. 
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Figure 3. SCs in nerve roots are strongly dependent on de novo FA synthesis. (a) Exemplary EM images of lumbar dorsal root (DR) and ventral root (VR) 
cross sections from mutant (cMU) and (CT) mice. In cMU roots, many SC-axon units remain blocked at the promyelinating stage (examples indicated by ar-
rows). Bars, 5 µm. (b) Corresponding graphs depicting complete quantification on fully reconstructed, EM-recorded root cross sections of the percentage of 
SC-axon units at the one-to-one versus myelinating stage. Data points represent n = 3 mice for each, CT and cMU (unpaired two-tailed two sample Student’s 
t test, P24 DR cMU vs. CT P = 0.0004, t = 11.10; P24 VR cMU vs. CT P < 0.0001, t = 32.94; P180 DR cMU vs. CT P = 0.0005, t = 10.39; and P180 
VR cMU vs. CT P = 0.0026, t = 6.694); **, P < 0.01; ***, P < 0.001. (c) Correlation of g-ratio versus axon diameter. Graphs show values obtained from 
at least 40 myelinated axons per root per mouse; n = 3 mice for each, CT and cMU. (d) Hypomyelination shown by g-ratio analysis. Data points represent 
n = 3 mice for each, CT and cMU (unpaired two-tailed two sample Student’s t test, P180 DR P = 0.0093, t = 4.704; P180 VR P = 0.0132, t = 4.243); 
**, P < 0.01; *, P < 0.05. (e) Immunoblots normalized to β-actin and corresponding graphs. n = 3 blots, each data point representing an independent 
experiment with an independent set of lysates from pooled DRs and VRs from three CT and three cMU mice (unpaired two-tailed two sample Student’s t 
test, FASN, P = 0.0003, t = 12.04; Oct6, P = 0.0328, t = 3.204; PMP22, P = 0.0250, t = 3.496); *, P < 0.05; ***, P < 0.001. (f) Representative im-
munohistochemistry of VRs of P24 CT and cMU showing myelinating SCs expressing myelin Protein Zero (P0). In cMU, myelinating axons are enriched in 
proximity to IB4-positive blood vessels. Bars, 50 µm. n = 3 mice for each, CT and cMU. (g) Representative toluidine-blue stained semithin cross sections of 
DRs and VRs (P180). In cMU, the areas covered by myelinated axons (red dotted line) are stereotypically positioned around blood vessels (false-colored in 
red). Bars, 50 µm; (insets) 25 µm. n = 3 mice for each, CT and cMU. (h) Graphs with relative distribution of myelinated axons, categorized by their distance 
from the closest blood vessel, in DRs and VRs (P180), CT and cMU. n = 3 mice for each, CT and cMU. Number (Nr) of blood vessels per toluidine blue–
stained nerve cross section; mean ± SEM; n = 3 mice for each, CT and cMU (unpaired two-tailed two sample Student’s t test, DR, P = 0.0405, t = 2.985; 
VR, P = 0.0213, t = 3.674). Bars represent mean ± SEM. 
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of Kv1.2 potassium channels in sciatic nerves of FASN mutant 
mice (Fig. 5, f and g).
The highly abundant phosphatidylinositol 38:4, phospha-
tidylcholine 34:1, and phosphatidylethanolamine 34:1 species 
were also reduced in nerves of FASN mutant mice, whereas the 
most abundant phosphatidylethanolamine, 36:2, showed a trend 
toward reduction (Fig. 5 d and Fig. S3). The observed lipidomic 
changes occurred without significant alterations in transcript 
levels of other key enzymes for FAs and derived lipid metab-
olism, i.e., stearoyl–coenzyme A desaturase (SCD1), the rate 
limiting enzyme for the synthesis of unsaturated FAs, and serine 
palmitoyl transferase long-chain subunit 1 (SPT LC1), a central 
enzyme in the synthesis of sphingolipids (Fig. 5 e). Moreover, 
we observed no significant accumulation of single lipid species 
(Fig. S3). These data establish that SC-intrinsic de novo FA syn-
thesis is essential to build up proper levels of palmitate, nones-
sential FAs, and complex lipids in peripheral nerves (Fig. 5 a).
Increased lipid dietary intake does 
not substitute for endogenous SC 
FA synthesis
We next tested whether a lack of endogenous FA synthesis in 
SCs could be rescued by increasing dietary lipid intake. Thus, 
we fed mutant and control mice a high-fat diet (HFD; 60% ca-
loric intake from fat and enriched in palmitic acid; complete 
list of FA contents is shown in Table S1) from embryonic day 
14 to 6 wk of age, according to an established protocol capable 
of rescuing defective astrocytic lipid synthesis in vivo (Cam-
argo et al., 2012; Fig.  6  a). This dietary intervention did not 
ameliorate the phenotype observed in nerves of FASN mutant 
mice (Fig. 6, b and c). On the contrary, mutants fed a HFD had 
a more pronounced phenotype (Fig.  6  b). Comparable to our 
previous experiments (Fig. 2, a and b), mutants fed a standard 
diet (STD) displayed 25.0 ± 5.86% of sciatic nerve SCs aber-
rantly blocked at the promyelinating stage (Fig. 6 b). This per-
centage was increased to 47.56 ± 3.39 in mutants fed a HFD 
(Fig. 6 b). The effect is unlikely to be ascribed to intrinsic det-
rimental effects of the diet per se, as we detected no change 
in nerves of control mice fed with a high-fat compared with 
an STD (Fig. 6 b and c). Rather it appears that nerves lacking 
SC-intrinsic FASN activity are uniquely susceptible to high-fat 
feeding. The HFD protocol also did not rescue hypomyelination 
of larger (≥3 µm in diameter) axons in sciatic nerves of mutants 
compared with controls (Fig. 6 d). These results indicate that 
SC myelination relies on endogenous synthesis of FAs. This de-
pendence cannot be circumvented by high dietary fats under the 
conditions that we applied.
FA synthesis in SCs triggers activation of 
the PPARγ transcriptional program
De novo synthesis of FAs may induce myelination through var-
ious mechanisms, such as contributing to lipid availability, by 
itself, regulating signaling pathways, or directly regulating ac-
tivity of transcription factors. Indeed, FAs bind to and induce 
a conformational change that leads to recruitment of cofactors 
and modulation of activity of the nuclear PPARs (PPARα, β, and 
γ; Ahmadian et al., 2013). We reasoned that decreased availabil-
ity of FAs and derived lipids in the PNS of FASN mutant mice 
could translate into reduced transcriptional activity of PPARs. 
We tested this hypothesis through a transcriptome Affymetrix 
Figure 4. Epineurial adipocytes may par-
tially sustain myelination in the absence of 
SC FA synthesis. (a) Schematic of morpholog-
ical changes in adipocytes during lipolysis. 
(b) Representative toluidine-stained cross 
sections of sciatic nerves depicting mature 
epineurial adipocytes in control mice (CT; A) 
and adipocytes with multiple lipid droplets in 
mutant mice (cMU; B and inset B′, and C and 
inset C′). Bars: (B and C) 20 µm; (B′ and C′, 
insets) 10 µm. n = 3 mice for each, CT and 
cMU. (c) Oil Red O staining of sciatic nerves 
(SNs), DRs, and VRs from P24 and P180 CT 
and cMU confirmed the presence of epineur-
ial adipocytes (examples indicated by arrows) 
in nerves, while revealing their absence in 
roots. Depicted images are representative of 
observed samples, n = 3 mice for each CT 
and cMU. Bars, 500 µm. 
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Figure 5. De novo FA synthesis in SCs is crucial for correct lipid composition of peripheral nerves. (a) Proposed hypothetical schema of sources of FAs and 
derived lipids in nerves. Proper nerve pools of nonessential (NonEss) FAs and derived complex lipids rely on endogenous FA synthesis in SCs (highlighted 
in orange), in contrast to essential (Ess) FAs, taken up through the diet, and conditional essential (CondEss) FAs, taken up through the diet or synthesized 
from essential FAs. (b) Reduction in palmitic acid and nonessential FAs (NEss), both long-chain (LCFAs) and very-long-chain (VLC FAs), in nerves of P24 mu-
tant (cMU) mice compared with controls (CT; unpaired two-tailed two sample Student’s t test, palmitic acid P = 0.0313, t = 2.796; NEss FAs P = 0.0106, 
t = 3.655; CondEss FAs P = 0.0640, t = 2.266; Ess FAs P = 0.1292, t = 1.758; LCFAs P = 0.0114, t = 3.597, VLC FAs P = 0.0208, t = 3.111); *, P < 
0.05. (c) Content of ceramides, cerebrosides, and sphingomyelin in nerves of P24 mutant (cMU) mice compared with controls (CT; unpaired two-tailed two 
sample Student’s t test, ceramides P = 0.0133, t = 3.471; cerebrosides P = 0.0045, t = 4.417; sphingomyelin P = 0.0157, t = 3.334); *, P < 0.05; **, P 
< 0.01. (d) Quantification of the two most abundant species of phosphatidylinositols (PIs), phosphatidylcholines (PCs), and phosphatidylethanolamines (PEs) 
in nerves of P24 cMU compared with CT (unpaired two-tailed two sample Student’s t test, PI 38:4 P = 0.0416, t = 2.583; PI 36:1 P = 0.0355, t = 2.701; 
PC 34:1 P = 0.0419, t = 2.577; PC 36:1 P = 0.2728, t = 1.207; PE 36:2 P = 0.0702, t = 2.199; PE 34:1 P = 0.0414, t = 2.587); *, P < 0.05. Data 
points represent n = 4 mice for each, CT and cMU, in entire lipidomic analysis. Lipid amounts normalized to the total protein contents of the sample (two 
pooled nerves per mouse). (e) Graphs of qRT-PCR analysis of SCD1 and SPT LC1 in sciatic nerves of P40 CT and cMU mice. qRT-PCR data normalized to 
β-actin, data points represent n = 3 mice for each, CT and cMU mice (unpaired two-tailed two sample Student’s t test, SCD1 P = 0.4292, t = 0.8786; SPT 
LC1 P = 0.9143, t = 0.1146). (f) Representative z-projections of stacks imaged by confocal microscopy of immunostaining of the juxtaparanodal potassium 
channel Kv1.2, the paranodal contactin 1, and the nodal neurofascin 186 proteins, in longitudinal sections of sciatic nerves from P30 CT and cMU mice, 
n = 3 mice for each, CT and cMU. Bar, 20 µm. (g) Graph showing quantification of Kv1.2 potassium channel localization, as the percentage of nodes with 
expression restricted to the juxtaparanode (juxtaparanodal), or aberrantly present in the paranode (paranodal), diffuse in the internode (internodal), or not 
detected. The graph represents values obtained from at least 40 nodes per mouse, from three mice for each, CT and cMU (two-way ANO VA, genotype 
P = 0.3739; F1,4 = 1, localization P < 0.0001; F3,12 = 312.6, with Sidak’s multiple comparisons test, cMU vs. CT juxtaparanodal P = 0.9966, t = 0.312; 
cMU vs. CT paranodal P = 0.9939, t = 0.3638; cMU vs. CT internodal P > 0.9999, t = 0.0539; cMU vs. CT not detected P = 0.9565, t = 0.6209). 
Bars represent mean ± SEM. 
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screening, comparing gene expression in sciatic nerves of P60 
mutants with those of control mice. Of the identified 276 regu-
lated (at least 1.5-fold) transcripts, the vast majority (246) was 
down-regulated (complete list in Table S3). MetaCore (Thom-
son Reuters) analysis revealed prominent down-regulation of the 
PPARγ transcriptional network (Fig. 7 a). We confirmed these 
results by quantitative RT-PCR (qRT-PCR) analysis of selected 
prototypical PPARγ targets (fatty acid translocase [CD36], lipo-
protein lipase [LPL], and fatty acid binding protein 4 [FABP4]; 
Everett et al., 2000; Ahmadian et al., 2013) using epineuri-
um-stripped P60 sciatic nerves (Fig. 7 b). FABP4 protein levels 
were also reduced in lysates of sciatic nerves dissected from P40 
mutants compared with controls by immunoblotting (Fig. 7 c). 
Based on these data, we propose that de novo FA synthesis in 
SCs activates the PPARγ transcriptional network.
The PPARγ agonist rosiglitazone can partially 
rescue SC myelination in the setting of 
deficient endogenous FA synthesis
Our data show that de novo FA synthesis in SCs is required to 
build up a correct lipid pool in nerves and suggest that this ef-
fect is critical for the activity of the transcription factor PPARγ. 
PPARs, in particular PPARγ, have been implicated in SC dif-
ferentiation and/or myelination (Yamagishi et al., 2008; Cao et 
al., 2012). Thus, we next addressed whether restoring PPARγ 
activity in SCs lacking FA synthesis would reverse the observed 
block in the onset of myelination. For this purpose, we first 
analyzed dissociated DR ganglion-based myelinating cultures 
obtained from FASN mutant and control mice (Fig. 8 a). Cul-
tures were treated with rosiglitazone, a potent and selective 
PPARγ agonist (Murphy and Holder, 2000; Marciano et al., 
2014), or with vehicle alone as control (Fig. 8 a). Cultures de-
rived from mutant mice displayed a strong reduction in myelin-
ation compared with controls (Fig. 8, a and b). This effect was 
partially rescued upon treatment with 20 µM rosiglitazone from 
the time of myelination induction (Fig. 8, a and b). Based on 
these findings, we asked whether this outcome could be trans-
lated to the in vivo condition. Thus, we administered rosiglita-
zone or vehicle intraperitoneally to FASN mutant mice at the 
time of myelination onset (P3), daily for 7 d, and compared the 
treated mutants with control mice injected with rosiglitazone 
or vehicle (Fig. 8 c). Consistent with our previous experiments, 
vehicle-injected mutant mice displayed a reduced percentage 
of myelinating SC-axon units compared with vehicle-injected 
control mice (63.44 ± 2.17% in vehicle-treated mutants vs. 
92.29 ± 0.81% in vehicle-treated controls; Fig.  8, d and e). 
Control mice injected with rosiglitazone showed no effect on 
myelination onset (93.22 ± 0.99% of SC-axon units at myelin-
ating stage; Fig.  8, d and e). Notably, we observed a signifi-
cant increase in the percentage of myelinating SC-axon units 
in rosiglitazone-treated compared with vehicle-treated mutant 
mice (78.26 ± 3.48% in rosiglitazone-treated mutants vs. 63.44 
± 2.17% in vehicle-treated mutants; Fig. 8, d and e). To address 
the effect of rosiglitazone on selected prototypical PPARγ tar-
gets, we analyzed a set of treated mice by qRT-PCR. We found 
significantly increased expression of FABP4 (1.40 ± 0.30 in 
Figure 6. Increased lipid dietary intake did 
not substitute for SC endogenous FA synthesis. 
(a) Schema depicting the experimental design. 
(b) Exemplary EM micrographs of sciatic nerve 
cross sections from mutant (cMU) and control 
(CT) mice fed an STD or HFD, and graphs of 
the percentage of one-to-one versus myelinat-
ing SC-axon units. Sciatic nerves (SNs) from 
cMU mice fed a standard or HFD showed SCs 
blocked at the promyelinating stage (examples 
indicated by arrows) and hypomyelinated 
axons (examples indicated by arrowheads). 
Bars, 5 µm. Data points represent n = 3 mice 
for each, CT and cMU, and for each, STD 
and HFD (unpaired two-tailed two sample Stu-
dent’s t test, STD cMU vs. CT, P = 0.0133, 
t = 4.240; HFD cMU vs. CT, P = 0.0002, 
t = 13.98; cMU HFD vs. STD, P = 0.0290, 
t = 3.334); #, P < 0.05; *, P < 0.05; ***, P 
< 0.001. #, Significance of high-fat compared 
with STD. *, Significance of cMU compared 
with CT. (c) Linear correlation of g-ratio versus 
axon diameter. The graph represents values 
obtained from at least 50 myelinated axons 
per mouse, from three mice for each, CT and 
cMU. (d) g-ratio analysis of larger (≥3 µm in 
diameter) axons shows no detectable ame-
lioration of sciatic nerve hypomyelination of 
cMU mice fed an HFD. Data points represent 
n = 3 mice for each, CT and cMU, and for 
each, standard and HFD (one-way ANO VA, 
treatment P = 0.0011, F3,8 = 15.22, with Si-
dak’s multiple comparisons test; cMU STD vs. 
CT STD P = 0.0436, t = 3.286; cMU HFD vs. 
CT HFD P = 0.0019, t = 5.660; CT HFD vs. CT 
STD P > 0.9999, t = 0.0; cMU HFD vs. cMU 
STD P = 0.1682, t = 2.373); *, P < 0.05; 
**, P < 0.01. Bars represent mean ± SEM.
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Rosiglitazone-treated mutants vs. 0.19 ± 0.17 in vehicle-treated 
mutants; Fig. S4 a). Other analyzed targets showed more vari-
able expression not reaching significance (CD36: 0.60 ± 0.16 in 
rosiglitazone-treated mutants vs. 0.25 ± 0.11 in vehicle-treated 
mutants; LPL: 0.30 ± 0.08 in rosiglitazone-treated mutants vs. 
0.21 ± 0.06 in vehicle-treated mutants; Fig. S4 a). We conclude 
that treatment with the PPARγ agonist rosiglitazone was able to 
partially release the block in myelination onset caused by the 
lack of FASN expression in SCs.
Discussion
Myelination is metabolically a highly demanding process, re-
quiring glial cells to timely and precisely increase and coordi-
nate RNA, protein and lipid synthesis, protein targeting, and 
massive membrane production (Taveggia et al., 2010; Pereira et 
al., 2012; Nave and Werner, 2014; Monk et al., 2015; Herbert 
and Monk, 2017). Many aspects of the network of metabolic 
changes critical for successful myelination remain to be eluci-
dated. In particular, how myelinating glial cells adapt to changes 
in lipid demands, i.e., the relative functional role of increased 
de novo lipogenesis versus lipid uptake, has not been fully ad-
dressed (Schmitt et al., 2015). In this study, we found that SCs 
do not substantially rely on FA synthesis for postnatal survival 
or proliferation. However, conditional depletion of FASN in 
SCs during embryonic development results in defective onset 
of myelination, impaired nerve lipid composition, and a chronic 
incapacity of SCs to myelinate efficiently.
The onset of PNS myelination is driven by the integration 
of multiple signaling axes, ultimately modulating the activity of 
master gene regulators of myelination (Jessen and Mirsky, 2005; 
Svaren and Meijer, 2008; Pereira et al., 2012; Glenn and Talbot, 
2013). FAs and derived lipids also modulate transcription by 
binding to PPARs, inducing a conformational change that leads 
to recruitment of cofactors and modulation of their activity (Ah-
madian et al., 2013). The interplay of FA synthesis and PPAR ac-
tivation has been intensively studied in adipocytes, macrophages, 
and liver cells (Lodhi et al., 2012; Ahmadian et al., 2013), but a 
role for PPARγ has been suggested also in oligodendrocyte pro-
genitor proliferation and differentiation by in vitro studies (Paint-
lia et al., 2010; Bernardo et al., 2013). PPARγ is expressed by 
Figure 7. FA synthesis in SCs triggers the 
activation of the PPARγ transcriptional program. (a) 
MetaCore analysis including all identified regulated 
transcripts (ANO VA with Benjamini-Hochberg 
false discovery rate for multiple testing correction, 
P < 0.05, ≥1.5-fold change) in sciatic nerves of 
mutant (cMU) mice compared with controls (CT) 
revealed inhibition of the PPARγ transcriptional 
network (schema as exported from Metacore 
version 6.29). Color intensity indicates degree 
of regulation. Symbols refer to protein category 
classes according to Metacore version 6.29 
classification (https ://download .genego .com /files 
/A4 _MetaCore _qrg _en .pdf). (b) Graph of qRT-
PCR analysis of FASN, CD36, LPL, and FABP4 in 
nerves of P60 CT and cMU mice. Data normalized 
to β-actin and to the mean of CT. Data points 
represent n = 3 mice for CT and n = 4 mice for cMU 
(unpaired two-tailed two sample Student’s t test, 
FASN, P = 0.0203, t = 3.350; CD36, P = 0.0023, 
t = 5.711; LPL, P = 0.0123, t = 3.823; FABP4, 
P = 0.0161, t = 3.567); *, P < 0.05; **, P < 
0.01. (c) Immunoblotting and corresponding graph 
showing decreased expression of FABP4 in lysates 
of sciatic nerves from P40 cMU compared with CT 
mice. Immunoblots normalized to β-actin. n = 3 
blots, each data point representing an independent 
experiment with an independent set of lysates from 
three CT and three cMU mice (unpaired two-tailed 
two sample Student’s t test, P = 0.0045, t = 5.764); 
**, P < 0.01. Bars represent mean ± SEM. 
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Figure 8. Rosiglitazone administration partially rescues dysmyelination of FASN mutant SCs. (a) Exemplary immunofluorescence of myelinating dissoci-
ated DR ganglia. Vehicle-treated control (CT), vehicle-treated mutant (cMU), and rosiglitazone-treated (20 µM) cMU mice. Treatment was started on the 
day when ascorbic acid was added. Bars, 100 µm. (b) Quantification of MBP-positive segments, 9 d after induction of myelination in CT and cMU treated 
cultures. Quantification was performed on four or more randomly selected fields of view per coverslip, on three to eight coverslips for each condition per 
experiment, in three independent experiments. Data points represent n = 17 coverslips of cultures from CTs treated with vehicle, n = 16 coverslips of cultures 
from cMUs treated with vehicle, and n = 12 coverslips of cultures from cMUs treated with rosiglitazone (Kruskal-Wallis, P < 0.0001, H = 37.78, with Dunn’s 
multiple comparison test; cMU vehicle vs. CT vehicle P < 0.0001; cMU rosiglitazone vs. cMU vehicle P = 0.0289); ***, P < 0.001; *, P < 0.05. (c) Schema 
depicting the experimental design of in vivo rosiglitazone or vehicle injections. (d) Exemplary electron micrographs of sciatic nerve cross sections of vehicle- 
or rosiglitazone-injected CT and cMU mice. Examples of promyelinating SC-axon units indicated by arrows. Bars, 2 µm. (e) Corresponding graph depicting 
complete quantification on fully reconstructed, EM-recorded cross sections of the percentage of myelinated axons (among sorted SC-axon units). Data points 
represent n = 7 mice each, for vehicle-injected CT, rosiglitazone-injected CT, and vehicle-injected cMU mice, and n = 10 mice for rosiglitazone-injected 
cMU mice (one-way ANO VA, treatment P < 0.0001, F3,27 = 27.65, with Tukey’s multiple comparisons test; cMU vehicle vs. CT vehicle P < 0.0001; cMU 
rosiglitazone vs. CT vehicle P = 0.0023; CT rosiglitazone vs. CT vehicle P = 0.9946; cMU vehicle vs. CT rosiglitazone P < 0.0001; cMU rosiglitazone vs. 
cMU vehicle P = 0.0012; cMU rosiglitazone vs. CT rosiglitazone P = 0.0011); **, P < 0.01; ***, P < 0.001. Bars represent mean ± SEM. 
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SCs (Cao et al., 2012), so we reasoned that decreased availability 
of endogenous FAs and their downstream lipids in the PNS of 
FASN mutant mice may ultimately translate into reduced PPARγ 
transcriptional activity similar to what was described for adipo-
cytes (Lodhi et al., 2012). Our results support this hypothesis. 
Moreover, we provide evidence that FASN-dependent lipogenic 
activation of the PPARγ transcriptional program is indeed likely 
to be important for the onset of SC myelination, because rosigl-
itazone administration was sufficient to ameliorate the dysmy-
elinating phenotype observed in FASN mutant SCs ex vivo and 
in vivo. We note that off-target interactions of rosiglitazone have 
been reported (Hoffmann et al., 2012), and we cannot currently 
exclude that such effects may play a role in our experimental set-
tings. Our data indicate that the accurate availability of FAs is not 
only required for correct myelin membrane production, but FA 
synthesis in SCs is of broader significance. We anticipate that de 
novo synthesized FAs may also contribute to PNS myelination by 
modulating additional pathways, e.g., targeting proteins to mem-
branes by palmitoylation. Addressing other contributing mecha-
nisms in FA-mediated regulation of myelination will be pursued 
in future investigations.
The mTORC1/SCAP/SRE BP axis has been inferred to be 
the main regulator of FASN transcription in myelinating SCs, 
and accordingly, SCAP and Raptor SC-conditional mutant mice 
showed early down-regulation of FASN expression (Verheijen 
et al., 2009; Norrmén et al., 2014). Nonetheless, neither mTOR, 
Raptor, SCAP, nor SRE BP1c mutant mice displayed chronic 
impairments in myelination onset in a large subset of myelin-
ation-competent axons, resembling the findings we report here 
caused by a lack of FASN expression in SCs (Verheijen et al., 
2009; Sherman et al., 2012; Norrmén et al., 2014; Cermenati 
et al., 2015). Rather, like many other previously studied lipo-
genic enzymes (Schmitt et al., 2015), the aforementioned pro-
teins appear to be mainly critical regulators of myelin growth 
(Verheijen et al., 2009; Sherman et al., 2012; Norrmén et al., 
2014; Schmitt et al., 2015). Currently unknown compensatory 
mechanisms might be at work in those mutants, leading to a 
delay rather than a block in myelination. Future work aimed at 
identifying the underlying molecular pathways is likely to be 
fruitful in dissecting the precise role of lipids and their metabo-
lism in peripheral nerve myelination.
Unexpectedly, we found that dependence of SCs on en-
dogenous de novo FA synthesis varies by developmental origin 
and/or location. SCs located in nerve roots (mostly derived from 
boundary cap cells [Maro et al., 2004; Aquino et al., 2006]) are 
more strongly reliant on SC-intrinsic FASN activity than SCs 
present in distal nerves (directly derived from the neural crest 
[Maro et al., 2004; Aquino et al., 2006]). Of particular interest 
in this context is our peculiar observation, specifically in FASN 
mutant sciatic nerves, that their associated epineurial adipo-
cytes contained small and multiple lipid vesicles, a sign of on-
going lipolysis and lipid release. Moreover, we found that nerve 
roots lacked epineurial adipocytes. Thus, it is conceivable that 
in the absence of endogenous FA synthesis in distal nerve SCs, 
increased lipid support from epineurial adipocytes has a com-
pensatory role to promote myelination. These findings highlight 
various compensatory mechanisms used by glial cells defective 
in lipid synthesis. In the CNS, oligodendrocytes with a shortage 
in lipid synthesis appear to be supported by horizontal lipid flux 
from astrocytes (Camargo et al., 2017). Failure of astrocytes 
to provide this support results in increased uptake of dietary 
lipids by myelinating oligodendrocytes (Camargo et al., 2017). 
Regarding SCs, our results do not exclude the possibility that 
in distal nerves and nerve roots different subpopulations with 
diverse metabolic demands may exist. These issues warrant fur-
ther investigation because they are not only relevant to our basic 
understanding of the mechanisms of peripheral nerve myelin-
ation in development but they may also have an impact on phys-
iological regulations related to lipid metabolism under different 
conditions in peripheral nerves, its diseases, and after injury.
Lipogenesis in myelinating glial cells has been thought 
to be mainly relevant for proper myelin growth and long-term 
axon-myelin maintenance (Schmitt et al., 2015). Our data re-
veal that a lipogenic switch in developing SCs is essential for 
correct initiation and efficiency of myelination. Overall these 
findings provide fundamentally novel information about the 
regulation of myelination, establishing the basis for future 
studies into the complex lipogenic regulation of glial function 




The Fasn floxed mice are available from the Semenkovich laboratory after 
executing a Material Transfer Agreement with Washington University. 
The Dhh-Cre mice are available from Jackson Labs (stock no. 012929).
Animal models
Mice (Mus musculus) homozygous for the FASN (Fasn) floxed allele 
(Chakravarthy et al., 2005; strain of origin: 129X1/SvJ, subsequently 
crossed with 129X1/SvJ*C57BL/6*DBA) were crossed with mice ex-
pressing Cre recombinase under the control of the Dhh promoter (Jae-
gle et al., 2003), to obtain Cre+ Fasnlox/lox mice (hereafter called mutant 
mice), and Cre− Fasnlox/lox or Fasnlox/wt (hereafter called control mice). 
Fasn floxed mice were backcrossed for at least three generations and 
DhhCre mice for more than 10 generations with C57BL/6 mice. Both 
male and female mice were used throughout all experiments. Mice 
were group-caged and kept in a 12-h light/dark cycle. Littermates and 
age-matched mice were assigned to experimental groups according to 
age and genotype. Animals were fed either an STD (3437; KLI BA NAF 
AG; Provimi KLI BA) or an HFD containing 60% fat calories (2127; 
KLI BA NAF AG, Provimi KLI BA), as previously described (Camargo 
et al., 2012). Pregnant mice received an HFD from day 14 of gesta-
tion, during pregnancy and lactation, until pups were weaned 3 wk after 
birth. At weaning, pups were separated and housed by gender, while 
continuously receiving the HFD. Mice fed an HFD were sacrificed at 
6 wk of age. FAs and cholesterol content (expressed as percentage val-
ues) in the administered HFD and STD are listed in Table S1.
All genotypes were determined by PCR on genomic DNA (Fasn prim-
ers: 5′-GGA TAG CTG TGT AGT GTA ACC AT-3′ and 5′-GGT CAC CCA 
GCA GGA AAG GGC-3′; Cre primers: 5′-TTC CCG CAG AAC CTG AAG 
ATG TTCG-3′ and 5′-GGG TGT TAT AAG CAA TCC CCA GAA ATG-3′).
All animal experiments were performed with the approval 
and in strict accordance with the guidelines of the Zurich Can-
tonal Veterinary Office.
In vivo rosiglitazone injections
Mice received daily intraperitoneal injections over 7 d (P3 to P9) of 
rosiglitazone (25 mg/kg/day at P3 and P4, and 50 mg/kg/day from P5 to 
P9; 71742; Cayman Chemicals) or vehicle (1× PBS) alone as control. 
Injected mice were sacrificed 12 h (at P10) after the last injection and 
tissues dissected for subsequent analysis.
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Behavior analysis
P40 control (n = 9) and mutant (n = 9) mice were tested during the light 
cycle. For motor behavior, a Rotarod (Ugo Basile) was set to accelerate 
from 4 to 40 rpm over 5 min. Four separate trials were scored at inter-
vals of 1 h. The average latency to fall from the rotating rod over three 
repeats run in succession was calculated for each trial. Subsequently, 
the same set of mice was used to test neuromuscular function with a 
Grip-Strength Meter (Ugo Basile). Mice were allowed to grip the metal 
bar with forelimbs and gently pulled, and the mean peak strength over 
five trials run in succession was calculated.
Myelinating dissociated DR ganglia cultures
Myelinating dissociated DR ganglia were established on Matrigel (BD 
Biosciences)-coated coverslips as previously described (Trimarco et 
al., 2014). For each experiment, DR ganglia were dissected from E13.5 
control and mutant mice into L15 (Life Technologies) medium and 
subsequently digested in 0.25% Trypsin/EDTA (Life Technologies) for 
45 min. Cells from mice of the same genotype were pelleted together 
and resuspended in Neurobasal (Life Technologies) supplemented with 
10% B27 (Life Technologies), 5 g/liter d-glucose (Sigma-Aldrich), 50 
ng/ml nerve growth factor (mNGF 2.5S; Millipore), 2 mM l-glutamine 
(Life Technologies), and penicillin/streptomycin (Life Technologies). 
Cells equivalent to 1.5 dissociated DR ganglia were plated per cover-
slip, and resuspension medium was changed every second day. My-
elination was induced after 9 d in vitro by adding 50 µg/ml ascorbic 
acid (Sigma-Aldrich) to MEM/Glutamax (Life Technologies) medium, 
supplemented with 10% FBS (Life Technologies), 5 g/liter d-glucose 
(Sigma-Aldrich), and 50 ng/ml 2.5S NGF (Millipore) in the absence of 
antibiotics. Cells were treated with either 20 µM rosiglitazone (71742; 
Cayman Chemicals) or an equal volume of vehicle (1× PBS). The me-
dium with the treatment was replaced every second day, and coverslips 
were processed after 18 d in vitro for immunofluorescent detection 
of MBP, NF-M, and DAPI.
Antibodies
The following antibodies were used: mouse anti–β-actin (WB 1:2,000, 
clone AC74; A2228; Sigma-Aldrich), goat anti–contactin 1 (IHC 
1:40; AF904; R&D Systems), rabbit anti–FABP4 (WB 1:1,000, clone 
D25B3; 3544; Cell Signaling), rabbit anti–FASN (WB 1:1,000, IHC 
1:200; Ab22759; Abcam), mouse anti–Kv1.2 (IHC 1:200; Ab192758; 
Abcam), rat anti–MBP (ICC and IHC 1:200, clone 12; MCA409S; 
Serotec), rabbit anti–neurofascin186 (IHC 1:300; Ab31719; Abcam), 
mouse anti–neurofilament M (ICC and IHC 1:200, clone NN18; 
MAB5245; Millipore), rabbit anti–oct6 (WB 1:1,000, provided by 
D. Meijer, University of Edinburgh, Edinburgh, Scotland, UK; Zwart et 
al., 1996), chicken anti-P0 (IHC 1:250; AB9352; Millipore), rabbit anti- 
PMP22 (WB 1:2,000, in-house; Snipes et al., 1992), goat anti–mouse 
IgG HRP coupled (WB 1:5,000; 115.035.003; Jackson Laboratories), 
goat anti–rabbit IgG HRP coupled (WB 1:5,000; 111.035.003; Jackson 
Laboratories), Isolectin B4 from Griffonia simplicifolia–conjugated to 
Alexa Fluor 594 (IHC 1:100; I21413; Invitrogen), donkey anti–goat 
IgG Alexa Fluor 488 coupled (IHC 1:500; A11055; Life Technologies), 
donkey anti–mouse IgG Alexa Fluor 546 coupled (IHC 1:500; A10036; 
Life Technologies), donkey anti–rabbit IgG Alexa Fluor 647 coupled 
(IHC 1:500; A31573; Life Technologies), goat anti–chicken IgG H-L 
Alexa Fluor 488 coupled (IHC 1:300; 103.545.155; Jackson Laborato-
ries), goat anti–mouse IgG H-L Alexa Fluor 488 coupled (IHC 1:300; 
111.545.144; Jackson Laboratories), goat anti–rabbit IgG H-L Cy3 
coupled (IHC 1:300; 111.165.144; Jackson Laboratories), goat anti–
Rat IgG H-L Cy5 coupled (IHC 1:300; 112–175-167; Jackson Labora-
tories), and goat anti–rat IgG H-L Alexa Fluor 594 coupled (IHC 1:300; 
112–585-143; Jackson Laboratories).
Immunoblotting
Tissues were homogenized with chilled mortar and pestle in CHA PS 
lysis buffer (50 mM NaH2PO, pH 8.0, 150 mM NaCl, 0.5% CHA PS, 
0.2% NaF, 0.01% Na3VO4, 0.04% EDTA, and proteases inhibitor cock-
tail [Roche]). Protein concentration was determined by NanoDrop 
Lite (NanoDrop Technologies). 10 µg of protein per lane was resolved 
on precasted NuPAGE 4–12% gradient gels or on linear SDS-PAGE 
and transferred to polyvinylidene difluoride membranes. Membranes 
were processed using standard immunoblotting procedures. Proteins 
were detected by binding primary antibodies to HRP-conjugated sec-
ondary antibodies and subsequently developed with Supersignal West 
Pico Chemiluminescent Substrate (Pierce). Chemiluminescent signal 
was detected, and images were acquired onto a Fusion FX7 system 
equipped with FusionCapt Advance FX7 software (Vilber Lourmat). 
Only images containing bands with no saturated pixels, confirmed by 
the software detection system, were used for subsequent quantification. 
Densitometry and quantification of relative levels were performed with 
ImageJ software. Full-length blots are shown in Fig. S4 b. Size markers 
refer to All Blue Precision Protein Standards (Biorad).
Transmission and scanning EM
Mice were anaesthetized by a terminal intraperitoneal injection of 
Eskonarkon (pentobarbital, 10% in saline solution [0.9% NaCl]), 
and perfused with 0.1 M phosphate buffer, pH 7.4, followed by 2.5% 
glutaraldehyde and 4% paraformaldehyde in 0.1 M phosphate buffer. 
Fixed tissues were dehydrated through a graded acetone series, post-
fixed in 2% osmium tetroxide overnight, and embedded in Spurrs resin 
(Electron Microscopy Sciences). Semithin sections were stained with 
1% toluidine blue (Sigma-Aldrich) for light microscopy analysis. Ul-
trathin sections (65 nm for transmission electron microscopy [TEM] 
and 99 nm for scanning EM) were cut on a UC-7 (Leica) or a Re-
ichert-Jung Ultra cut E ultramicrotome. Sections were deposited onto 
copper grids with carbon film (Electron Microscopy Sciences) for TEM 
or onto indium tin oxide coverslips (Optic Balzers) for scanning EM, 
and counterstained with 2% uranyl acetate and 1% lead citrate. For 
TEM, multiple random fields of sciatic nerves/roots were imaged with 
a Morgagni (FEI) transmission electron microscope. For scanning EM, 
the entire surface of sciatic nerve/root cross sections was imaged using 
the in-lens detector of a Zeiss Merlin FEG scanning EM operating at 
2 KeV, attached to the ATL AS module (Zeiss). The entire nerve/root 
panorama was acquired as multiple individual images, with overlap 
between adjacent ones. Alignment and merging of the images were 
performed using FIJI (ImageJ) and Photoshop CS5 or CS6 (Adobe). 
Brightness and contrast of the images were adjusted for optimal de-
tection of the structures.
Immunofluorescence, TUN EL, and EdU-proliferation assay
For immunohistochemistry, mice were anaesthetized by terminal in-
traperitoneal injection of Eskonarkon (pentobarbital, 10% in saline 
solution) and intracardially perfused with 1× PBS followed by 4% para-
formaldehyde and 5% sucrose in 1× PBS. Dissected tissues were post-
fixed in 4% paraformaldehyde and 5% sucrose in 1× PBS overnight and 
cryoprotected in 30% sucrose in 1× PBS for 24 h. Tissues were embed-
ded in Tissue-Tek OCT (Sakura). 10-µm sections were cut on a cryostat 
and transferred to SuperFrost Plus (Thermo Scientific)–coated slides.
All sections from samples to be compared were processed simul-
taneously. Sections were blocked for 1 h with 10% donkey (for node 
of Ranvier stainings) or goat serum (Invitrogen) and 1% Triton X-100, 
in 1× PBS, and incubated with primary antibodies overnight (4°C). 
Tissue sections were washed (1× PBS) and incubated with secondary 
antibodies (1 h at room temperature). After incubation with DAPI and 
washing (1× PBS), sections were coverslipped with Shandon Immu-
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Mount (Thermo Scientific). Cell proliferation was analyzed using the 
Click-iT EdU assay (Invitrogen), according to the manufacturer’s pro-
tocol. Apoptotic cell death was analyzed by TUN EL staining using bio-
tin-labeled UTP and Alexa Flour 546–conjugated streptavidin complex 
according to the manufacturer’s instructions (Roche Diagnostics). Cell 
proliferation and apoptosis were quantified with ImageJ software. The 
experimenter was blind to the genotype.
Oil Red O staining
Dissected tissues were processed as previously described (Nadra et al., 
2012). In brief, they were washed in 1× PBS and incubated 10 min in 
Oil Red O (O1391; Sigma-Aldrich; 0.5% in isopropanol), previously 
diluted 3:2 in water, and filtered. After washing 10 min in water, tissue 
was mounted on Superfrost Plus glass slides (Thermo Scientific) with 
Vectashield Mounting medium (Vectashield) for subsequent imaging 
under light microscopy.
Microscope image acquisition
Images of tissue sections stained by immunofluorescence, Click-EdU 
labeling, and TUN EL staining were acquired by using the Zen 2 soft-
ware (Zeiss) on an AxioImager M2 microscope (Zeiss) equipped with 
a high-resolution camera (pco.edge; sCMOs Cameras) and with either 
a Plan Apochromat 20×/0.8 air objective (420651-9911; Zeiss) or with 
a 40× Plan Apochromat 40×/0.95 air objective (420661-9970; Zeiss). 
Single-channel images were merged to create composite multichannel 
images with ImageJ software.
Images of Oil Red O– and toluidine-stained tissue sections were 
acquired by using AxioVision 4.8 software (Zeiss) on a Zeiss Axioskop 
2 microscope equipped with an AxioCam HRc camera (Zeiss) and with 
either a Plan-Neofluar 20×/0.5 air objective (440341-9904; Zeiss), a 
Plan-Neofluar 40×/1.30 oil immersion objective (1022-818; Zeiss), or 
a Plan-Neofluar 100×/1.30 oil immersion objective (440480; Zeiss).
Images of nodal stainings were acquired on an LSM 780-FCS 
laser scanning confocal microscope (Zeiss) equipped with a Plan-Apo-
chromat DIC 63×/1.4 oil immersion objective (421782-9900-799; 
Zeiss) using an argon laser (488 nm), a solid-state laser (561 nm), and 
a helium-neon laser (633 nm). For signal detection two Quasar photo-
multipliers and 32 photomultiplier GaAsP detectors were used.
All images were acquired at room temperature (20–24°C).
Lipidomics
Chemicals were purchased either from Merck or Sigma-Aldrich. Lipid 
standards were obtained from Avanti Polar Lipids. Analysis of lipid 
species was performed according to published methods (Fauland et al., 
2011). Samples were extracted with methyl tert-butyl ether (Matyash 
et al., 2008). Lipid extracts were evaporated and resuspended in 1 ml 
chloroform/methanol (1:1, vol/vol). Each lipid extract was then split 
for analysis of total FAs (350 µl), positive electrospray ionization (ESI) 
liquid chromatography-tandem mass spectrometry (LC-MS/MS; 18 µl) 
and negative ESI LC-MS/MS (18 µl). Lipid extracts for LC-MS/MS 
analysis were evaporated and spiked with a mix of quantitative LIP 
ID MAPS internal standards, and 5-µl spiked samples were injected 
onto a 1.9-µm Hypersil GOLD C18 (Thermo Scientific), 100 × 1 mm 
HPLC column mounted in an Accela HPLC instrument (Thermo Sci-
entific). Data acquisition was performed by Fourier transform ion cy-
clotron resonance–MS (LTQ-FT model; Thermo Scientific) full scans 
at a resolution of 200 k and <2 ppm mass accuracy with external cal-
ibration. Nominal mass resolution product ion spectra were acquired 
in preview mode at the LTQ. A chromatography with electron impact 
mass spectrometry of total FAs (free plus esterified) was performed. 
Lipid extracts were dried and suspended in 1 ml methanolic NaOH. 
After 10-min incubation at 80°C, samples were cooled for 5 min on 
ice. Then, 1 ml BF3 was added and incubated for 10 min at 80°C. FA 
methyl esters were extracted with 1 ml saturated NaCl and 2 ml hex-
ane. The hexane phase was dried, and methyl esters were dissolved 
in 1.5  ml hexane. A Trace–dual-stage quadrupole GC-MS (Thermo 
Scientific) equipped with a 30-m column (model TR-FAME; Thermo 
Scientific) was used for analysis. Helium was used as the carrier gas at 
a flow of 1.3 ml/min, in split mode, at 250°C injector temperature. An 
initial oven temperature of 150°C was held for 0.5 min, and then the 
temperature was increased to 180°C at a rate of 10°C/min. This was 
followed by a further increase to 190°C at a rate of 0.5°C/min and then 
increased to 250°C at a rate of 40°C/min and kept for 3 min. The mass 
spectrometer was run in electron impact mode, and FAs were detected 
in full scan of 80–400 mass per charge number. Source temperature 
was set to 250°C and the transfer line temperature to 200°C. Internal 
standards used in LC-MS were (LIP ID MAPS identification number 
[LM], lipid shorthand nomenclature [PE, phosphatidylethanolamine; 
PS, phosphatidylserine; PC, phosphatidylcholine; PI, phosphatidy-
linositol], amount/sample): LM-1100, PE 12:0/13:0, 160 pmol; LM-
1102, PE 17:0/20:4, 160 pmol; LM-1103, PE 21:0/22:6, 160 pmol; 
LM-1104, PE 17:0/14:1, 160 pmol; LM-1302, PS 17:0/20:4, 240 pmol; 
LM-1300, PS 12:0/13:0, 240 pmol; LM-1304, PS 17:0/14:1, 240 pmol; 
LM-1000, PC 12:0/13:0, 200 pmol; LM-1002, PC 17:0/20:4, 200 
pmol; LM-1003, PC 21:0/22:6, 200 pmol; LM-1004, PC 17:0/14:1, 
200 pmol; LM-1601, LPC 17:1, 80 pmol; LM-6002, sphingolipid mix, 
120 pmol; LM-1500, PI 12:0/13:0, 320 pmol; LM-1502, PI 17:0/20:4, 
320 pmol, LM-1504, PI 17:0/14:1, 320 pmol.
Data were processed by Lipid Data Analyzer software as pre-
viously described (Hartler et al., 2011), relying on exact mass and 
retention time. Annotation of lipid species followed the shorthand no-
menclature of the International Lipid Classification and Nomenclature 
Committee (Liebisch et al., 2013). During the lipid extraction proce-
dure, the fraction containing proteins was lyophilized. Proteins were 
dissolved in lysis buffer (1% Rapigest [Waters/Millipore], Tris, pH 7.4, 
and 0.1 mM EDTA) and quantified onto a NanoDrop Lite (NanoDrop 
Technologies) spectrophotometer. Lipid amounts were normalized to 
the sample total protein content.
RNA isolation
Dissected tissue was grinded in Trizol (Sigma-Aldrich) into a liq-
uid-nitrogen precooled mortar. Grinded powder was resuspended in 
Trizol and RNA extracted by chloroform/isopropanol standard puri-
fication protocol. Quantity and quality of isolated RNA were deter-
mined with NanoDrop ND 1000 (NanoDrop Technologies), Qubit 2.0 
Fluorometer (Life Technologies), and Bioanalyzer 2100 (Agilent). 
Further processed samples had a 260:280-nm ratio within 1.8–2.1 and 
28S:18S ratio within 1.5–2.
Affymetrix transcriptome analysis
Amplified RNA (aRNA) was prepared with a GeneAtlasTM 3′IVT 
Express kit (Affymetrix) according to the manufacturer’s instructions. 
RNA samples (100 ng) were reverse-transcribed into first-strand cDNA 
with T7 oligo(dT) primer. DNA polymerase and RNaseH were used 
simultaneously to synthesize double-stranded cDNA and degrade the 
RNA. Double-stranded cDNA was amplified in vitro and labeled with 
biotin to obtain biotin-modified aRNA, which was further purified by 
using RNA Binding Beads to remove unincorporated nucleoside tri-
phosphates, salts, enzymes, and inorganic phosphate. aRNA yield 
and size distribution were determined with NanoDrop ND 1000 and 
Bioanalyzer 2100. 10 µg of biotin-labeled aRNA was fragmented to 
reach a range of 35–200-nt aRNA fragments. For array hybridization, 
biotin-labeled aRNA samples were mixed in 150 µl WT Hybridization 
Cocktail (Affymetrix) containing Hybridization Controls and Control 
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Oligonucleotide B2 (Affymetrix). Samples were hybridized to Affy-
metrix MG-430 PM Array Strip (Affymetrix) in a GeneAtlas Hybrid-
ization Station (Affymetrix) for 16 h at 45°C. Arrays were washed in 
a GeneAtlas Fluidics Station (Affymetrix). The fluorescent intensity 
emitted by the labeled targets was measured onto a GeneAtlas Imag-
ing Station (Affymetrix). Raw data were exported to Excel and subse-
quently analyzed by GeneSpring GX (Agilent) by applying an RMA 
summarization algorithm with the baseline set to the median of all sam-
ples. Entities were filtered based on their corrected p-values calculated 
asymptotically with ANO VA analysis and Benjamini-Hochberg false 
discovery rate for multiple testing correction. The p-value cut-off was 
set at 0.05. A final threshold of ≥1.5-fold increase or decrease in the 
expression level of each single transcript was applied. Pathway analysis 
was run using Metacore (Thompson Reuters) software.
Microarray data are MIA ME compliant and have been deposited 
at the GEO repository database with accession code GSE71373.
Quantitative real-time PCR
RNA samples were reverse-transcribed to cDNA with oligo(dT) random 
primers in the presence of RNaseOUT (Invitrogen) with Superscript III 
RT (Invitrogen) or with the Maxima RT kit (Thermo Scientific). Tar-
geted sequences were amplified with exon/exon boundaries spanning 
probes and detected by measurement of SYBRgreen on a LightCycler 
480 (Roche). Cp values were determined with the LightCycler 480 
software (Roche). Sequences of used primers are available in Table S2.
Statistical analysis
Statistics were analyzed by using GraphPad Prism v6.01. Gaussian 
distribution of data was tested with a D’Agostino-Pearson omnibus 
normality test. When Gaussian distribution could not be tested, be-
cause of a low number, data were assumed to be normally distrib-
uted. Variance was assumed to be equal between groups of data. For 
normally distributed data, statistical significance was determined by 
using an unpaired two-sample Student’s t test for two-group compar-
isons. Multiple groups analysis was performed with one- or two-way 
ANO VA and post hoc test as detailed in text and figures. Data show 
mean ± SEM of three independently run experiments unless other-
wise specified in text and figures. Significance was set at *, P < 0.05; 
**, P < 0.01; and ***, P < 0.001. No statistical methods were used 
to predetermine sample size, but our sample sizes are similar to those 
generally used in the field.
Data and software availability
Microarray datasets have been deposited in the National Center for 
Biotechnology Information’s Gene Expression Omnibus database, ac-
cession no. GSE71373. Full-length Western blots are shown in Fig. S4 
b. All software is freely or commercially available.
Online supplemental material
Fig. S1 shows that de novo FA synthesis in SCs is dispensable toward 
SC early postnatal survival and proliferation and not essential for axo-
nal maintenance. Fig. S2 shows that SCs in distal nerves, engaged either 
with predominantly sensory or motor fibers, appear equally dependent 
on de novo FA synthesis for efficient onset of myelination. Fig. S3 
shows lipid profiles of sciatic nerves of control and FASN mutant mice. 
Fig. S4 shows expression of PPARγ targets after rosiglitazone treat-
ment and full-length immunoblots. Table S1 shows FAs and cholesterol 
content (expressed as percentage values) in the administered HFD and 
STD. Table S2 shows qRT-PCR probes and primers. Table S3 shows 
regulated transcripts in sciatic nerves of P60 mutant mice compared 
with control mice identified by Affymetrix Transcriptome Analysis.
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Figure S1. De novo FA synthesis in SCs is dispensable toward SC early postnatal survival and proliferation and not essential for axonal maintenance. 
(a) No detected statistically significant difference in the percentage of proliferating cells in cryosections of P0 and P5 sciatic nerves of conditional mutant 
(cMU) mice compared with control (CT) mice. Data points represent n = 3 mice for each, cMU and CT (unpaired two-tailed two sample Student’s t test, P0 
P = 0.5179, t = 0.7083; P5 P = 0.6171, t = 0.5412). (b) No statistically significant difference was detected in the percentage of apoptotic cells in cryosec-
tions of P0 and P5 sciatic nerves of cMU mice compared with CT mice. Data points represent n = 3 mice for each, cMU and CT (unpaired two-tailed two 
sample Student’s t test, P0 P = 0.7850, t = 0.2918; P5 P = 0.3414, t = 1.079). (c) Increased expression levels of the transcription factor Oct6 in protein 
lysates from sciatic nerves of P40 cMU mice compared with CT mice. Immunoblots were normalized to β-actin. n = 3 blots, each data point represents 
an independent experiment with an independent set of lysates from three CT and three cMU mice (unpaired two-tailed two sample Student’s t test, Oct6 
P = 0.0083, t = 4.855); **, P < 0.01. (d) EM images depicting compressed myelinated axons (examples indicated by arrows) presumably because of 
vacuolization (examples marked by stars) in sciatic nerves of P180 mutant mice (cMU). Bar, 5 µm. (e) Graph with quantification of the number of myelin-
ated axons with vacuolation per fully reconstructed sciatic nerve cross section, at P180. n = 3 mice for each, control (CT) and cMU (unpaired two-tailed 
two sample Student’s t test, P = 0.0390, t = 3.204), *, P < 0.05. (f) Graph showing quantification of total number of sorted axons per fully reconstructed 
sciatic nerve cross section at EM level at P180. n = 3 mice for each, CT and cMU (unpaired two-tailed two sample Student’s t test, P = 0.1652, t = 1.696). 
Bars represent mean ± SEM. 
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Figure S2. SCs in distal nerves, engaged either with predominantly sensory or motor fibers, appear equally dependent on de novo FA synthesis for 
efficient onset of myelination. Representative EM images of P24 mutant (cMU) and control (CT) saphenous and quadricep nerve cross sections. Whereas 
individual large-caliber axons (>1 µm in diameter) are myelinated in CT nerves, SC-axon units at the promyelinating stage are still present in cMU (examples 
indicated by arrows). Thinly myelinated axons are also present in cMU nerves (examples indicated by arrowheads). Bars, 5 µm. Corresponding graphs 
show quantification of the percentage of SC-axon units at the one-to-one versus myelinating stage. Significance was calculated compared with controls. 
Data points represent n = 3 mice for each, CT and cMU (unpaired one-tailed two sample Student’s t test [hypothesis of up-regulation of one-to-one SC-axon 
units in cMU compared with CT, as previously observed in roots and sciatic nerves, see Figs. 2 and 3], quadricep P = 0.0420, t = 2.288; saphenous 
P = 0.0008, t = 7.524); ***, P < 0.001; *, P < 0.05. Bars represent mean ± SEM. 
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Figure S3. Lipid profiles of sciatic nerves of control and FASN mutant mice. Lipids extracted from sciatic nerves of P24 control (CT) and mutant (cMU) 
mice were identified and quantified by LC-MS. (a) Depicted are individual total FAs (TFA), subdivided in nonessential (Non Ess; which can be synthesized), 
essential (Ess; which must be taken up through the diet), and conditional essential (Cond Ess; which can either be taken up through the diet or synthesized 
from essential FAs). Of the two essential FAs, linoleic acid and α-linolenic acid, only linoleic acid (18:2n6) showed a quantity detectable by our analysis. 
Individual species of all identified ceramides (b), cerebrosides (c), sphingomyelin (d), phosphatidylinositols (PIs; e), and of the 10 highest phosphatidyletha-
nolamines (PEs; f) and phosphatidylcholines (PCs; g) are shown. Lipid amounts were normalized to the total protein content of the sample. Significance was 
calculated compared with controls. Data points represent n = 4 mice for each, CT and cMU (unpaired two-tailed two sample Student’s t test, TFAs—18:1n9 
P = 0.0062, t = 4.126; 16:0 P = 0.0313, t = 2.796; 18:0 P = 0.0331, t = 2.754; 18:1n11 P = 0.0228, t = 3.042; 16:1n7 P = 0.0796, t = 2.108; 
14:0 P = 0.2053, t = 1.420; 24:0 P = 0.0212, t = 3.096; 22:0 P = 0.0214, t = 3.091; 20:0 P = 0.0058, t = 4.182; 20:4n6 P = 0.0654, t = 2.251; 
22:6n3 P = 0.5091, t = 0.7017; 22:4n6 P = 0.0339, t = 2.735; 20:3n6 P = 0.0867, t = 2.046; 22:5n3 P = 0.0064, t = 4.100; 18:2n6 P = 0.1292, 
t = 1.758; ceramides—24:1 P = 0.0305, t = 2.817; 24:0 P = 0.0111, t = 3.621; 18:0 P = 0.0141, t = 3.422; 22:0 P = 0.0124, t = 3.527; 20:0 P = 
0.0160, t = 3.322; 24:2 P = 0.7925, t = 0.2750; cerebrosides—24:1 P = 0.0025, t = 4.975; 24:0 P = 0.0522, t = 2.374; 22:0 P = 0.0206, t = 3.121; 
18:0 P < 0.0001, t = 9.396; 24:2 P = 0.9254, t = 0.09762; 20:0 P = 0.0090, t = 3.798; 22:1 P = 0.5524, t = 0.6293; 16:0 P = 0.0342, t = 2.730; 
sphingomyelin—24:1 P = 0.0116, t = 3.584; 24:0 P = 0.0040, t = 4.527; 24:2 P = 0.1726, t = 1.548; 18:0 P = 0.0033, t = 4.707; 16:0 P = 0.0773, 
t = 2.129; 22:0 P = 0.0044, t = 4.432; 20:0 P = 0.0016, t = 5.473; 22:1 P = 0.1303, t = 1.752; 16:1 P = 0.3844, t = 0.9381; 14:0 P = 0.1875, t = 
1.487; 18:1 P = 0.1058, t = 1.903; 20:1 P = 0.8166, t = 0.2423; PIs—38:4 P = 0.0416, t = 2.583; 36:1 P = 0.0354, t = 2.703; 40:6 P = 0.1290, t = 
1.760; 36:2 P = 0.0179, t = 3.232; 36:4 P = 0.1149, t = 1.843; 38:5 P = 0.1431, t = 1.684; 38:6 P = 0.4832, t = 0.7471; PEs—36:2 P = 0.0702, t 
= 2.199; 34:1 P = 0.0414, t = 2.587; 38:4 P = 0.9570, t = 0.0563; 38:5 P = 0.1397, t = 1.702; 38:6 P = 0.4854, t = 0.7433; 40:6 P = 0.7055, t = 
0.3965; 36:1 P = 0.2995, t = 1.135; 36:3 P = 0.6899, t = 0.4188; 36:4 P = 0.1016, t = 1.932; 40:4 P = 0.6673, t = 0.4518; PCs—34:1 P = 0.0419, 
t = 2.577; 36:1 P = 0.2728, t = 1.207; 36:2 P = 0.2714, t = 1.211; 32:0 P = 0.7655, t = 0.3121; 32:1 P = 0.3562, t = 0.9993; 34:2 P = 0.2545, t 
= 1.260; 30:0 P = 0.7716, t = 0.3037; 36:4 P = 0.3984, t = 0.9090; 42:1 P = 0.0182, t = 3.219; 36:3 P = 0.3024, t = 1.128); *, P < 0.05; **, P < 
0.01; ***, P < 0.001. Bars represent mean ± SEM. 
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Figure S4. Expression of PPARγ targets after rosiglitazone treatment (related to Fig. 8) and full-length immunoblots (related to Figs. 1, 3, 7, and S1). 
(a) Graph of qRT-PCR analysis of FABP4, CD36, and LPL in sciatic nerves of P10 mutant (cMU) mice after vehicle or rosiglitazone treatment. Data normalized 
to β-actin and to the mean of control (CT) vehicle-injected. Data points represent n = 5 mice for cMU vehicle-injected, n = 12 mice for cMU rosiglitazone- 
injected (unpaired two-tailed Mann-Whitney test, FABP4 P = 0.006, U = 5; CD36 P = 0.2023 U = 17.5; LPL P = 0.7426 U = 26.5). **, P < 0.01. Bars 
represent mean ± SEM. (b) Full-length immunoblots. Cropped regions displayed in main figures are highlighted (dashed boxes). After transfer, membranes 
were cut as follows: Fig. 1 b, two pieces, cut below 75 kD; Fig. 3 e, three pieces, cut below 100 kD and 37 kD; Fig. 7 c, three pieces, cut below 75 kD 
and 25 kD; and Fig. S1 c, two pieces, cut below 100 kD. Gels were used as 4–12% Nu-PAGE precasted gradient gels (Fig. 3 e and Fig. S1 c) and 12% 
SDS-PAGE gels (Fig. 1 b and Fig. 7 c). Numbers refer to the molecular mass size markers (in kilodaltons). 
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Table S1. Fatty acids and cholesterol content (expressed as percentage values) in the administered high fat (HFD) and standard (STD) diets
Fat species Fatty acid Nomenclature Amount present in HFD  
(KLI BA NAF AG, 2127)
Amount presentin STD  
(KLI BA NAF AG, 3437)
% %
Butyric acid C4 0.000 0.000
Caproic acid C6 0.000 0.000
Caprylic acid C8 0.000 0.000
Capric acid C10 0.000 0.000
Lauric acid C12 0.030 0.002
Myristic acid C14 0.440 0.008
Pentadecanoic acid C15 0.000 0.002
Palmitic acid C16 8.220 0.719
Margaric acid C17 0.000 0.004
Stearic acid C18 4.500 0.157
Arachidic acid C20 0.020 0.010
Behenic acid C22 0.000 0.004
Lignoceric acid C24 0.000 0.012
Myristoleic acid C14:1 0.170 0.001
Palmitoleic acid C16 :1c7 1.000 0.052
Oleic acid C18 :1c9 14.120 1.024
Eicosenic acid C20 :1c9 0.000 0.013
Erucic acid C22 :1c9 0.000 0.002
Linoleic acid C18 :2c9c12 4.810 2.107
Linolenic acid C18 :3c9c12c15 0.590 0.212
Octadecatetraenoic acid C18:4 (n-3) 0.000 0.000
Arachidonic acid C20:4 (n-6) 0.560 0.009
Eicosapentanoic acid C20:5 (n-3) 0.000 0.000
Clupanodonic acid C22:5 (n-3) 0.000 0.001
Docosahexanoic acid C22:6 (n-3) 0.000 0.001
Cholesterol 0.030 0.030
Table S2. qRT-PCR probes and primers
Probe Forward primer (5′–3′) Reverse primer (5′–3′)
β-actin TTC TTT GCA GCT CCT TCG TT ATG GAG GGG AAT ACA GCCC
CD36 AGA TGA CGT GGC AAA GAA CAG CCT TGG CTA GAT AAC GAA CTC TG
FABP4 GGG AAC CTG GAA GCT TGT CT ACT CTC TGA CCG GAT GGT GA
Fasn GTT GGC CCA GAA CTC CTG TA GTC GTC TGC CTC CAG AGC
LPL ATG GAT GGA CGG TAA CGG GAA CCG ATA CAA CCA GTC TAC TACA
SCD1 CAG CCG AGC CTT GTA AGT TC GCT CTA CAC CTG CCT CTT CG
SPT LC1 ACG AGG CTC CAG CAT ACC AT TCA GAA CGC TCC TGC AAC TTG
Provided online is Table S3 in Excel. Table S3 shows regulated transcripts (ANO VA with Benjamini-Hoch-
berg false discovery rate for multiple testing correction, P < 0.05, ≥1.5-fold change as up- or down-reg-
ulation) in sciatic nerves of P60 mutant mice compared with control mice identified by Affymetrix 
Transcriptome Analysis.
